The preferred agents for treating primary aldosteronism and treatment-resistant hypertension are MR antagonists (spironolactone and eplerenone) [1, 3], although long-term use of spironolactone is associated with a greater risk of gynecomastia and sexual dysfunction due to off-target effects [1, 4]. This evidence concerns the gene NR3C2 and Gynecomastia.